Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy

Hepatology Research

Volumn 41, Issue 12, 2011, Pages 1145-1152

  Itoh, Yoshito ^a   Nishimura, Takeshi ^a   Yamaguchi, Kanji ^a   Yokomizo, Chihiro ^a   Fujii, Hideki ^a   Minami, Masahito ^a   Nagao, Yasuyuki ^b   Sumida, Yoshio ^d   Hashimoto, Hiroaki ^c   Umemura, Atsushi ^c   Shima, Toshihide ^c   Okanoue, Takeshi ^c   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^d Nara City Hospital   (Japan)

Author keywords

Chronic hepatitis C; Genotype 2; Hepatic fibrosis; Hepatic steatosis; Homeostasis model assessment insulin resistance

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 82255185615     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00886.x     Document Type: Article

References (31)

1. Manns MP, McHutchinson JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Akuta N, Suzuki F, Tsubota A etal. Efficacy of interferon monotherapy to 394 consecutive naïve cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartile interaction of viral, host and interferon treatment-related factors. J Hepatol 2002; 37: 831-6.
4. Akuta N, Suzuki F, Suzuki Y etal. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005; 75: 550-8.
5. Poynard T, Ratziu V, McHutchison J etal. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
6. Poustchi H, Negro F, Hui J etal. Insulin resistance and response to therapy in patients with chronic hepatitis C virus genotype 2 and 3. J Hepatol 2008; 48: 28-34.
7. Rodriguez-Torres M, Govindarajan S, Diago M etal. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 0r 24weeks. Liver Int 2009; 29: 237-41.
8. Mangia A, Santoro R, Minerva N etal. Peginterferon alfa-2b and ribavirin for 12 vs. 24weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
9. von Wagner M, Huber M, Berg T etal. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
10. Shiffman ML, Suter F, Bacon BR etal. Peginterferon alfa-2a and ribavirin for 16 or 24weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
11. Dalgard O, Bjøro K, Ring-Larsen H etal. Pegylated interferon alfa and ribavirin for 14 versus 24weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
12. Lagging M, Langeland N, Pedersen C etal. Randomized comparison of 12 or 24weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-45.
13. Yu ML, Dai CY, Huang JF etal. A randomised study of peginterferon and ribavirin for 16 versus 24weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
14. Mangia A, Minerva N, Bacca D etal. Determinants of relapse after a short (12weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49: 358-63.
15. Rodriguez Torres M, Rios Bedoya CF, Ortiz-Lasanta G, Purcell-Arevalo D, Marxuach-Cuetara A, Jimenez-Rivera J. Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180mcg/week and 800 mg daily of ribavirin for 24weeks. J Med Virol 2008; 80: 1576-80.
16. Ichida F, Tsuji T, Omata M etal. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996; 6: 112-19.
17. Inoue Y, Hiramatsu N, Oze T etal. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2010; 17: 336-44.
18. Kurosaki M, Tanaka Y, Nishisa N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-48.
19. Leandro G, Mangia A, Hui J etal. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
20. Patton HM, Patel K, Behling C etal. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
21. Lok AS, Everhart JE, Chung RT etal. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 2007; 5: 245-54.
22. Lerat H, Kammoun HL, Hainault I etal. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem 2009; 284: 33466-74.
23. Vanni E, Abate ML, Gentilcore E etal. Site and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis. Hepatology 2009; 50: 697-706.
24. Miyaaki H, Ichikawa T, Nakao K etal. Predictive value of suppressor of cytokine signal 3(SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res 2009; 39: 850-5.
25. Tillmann HL. Does the presence of hepatic steatosis influence the efficacy of antiviral treatment in patients with hepatitis C? Nat Clin Pract 2007; 4: 548-49.
26. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predict hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
27. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
28. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
29. Sakamoto N, Nakagawa M, Tanaka Y etal. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotipic differences between genotype genotype 2a and 2b. J Med Virol 2011; 83: 871-8.
30. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotype 2a and 2b. J Hepatol 2011; 54: 408-14.
31. De Compadri P, Koleva D, Mangia A, Motterlini Stat Sci N, Garattini L. Cost minimisation analysis of 12 or 24weeks of peginterferon alfa2b + ribavirin for hepatitis C virus. J Med Econ 2008; 11: 151-63.